GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up. I think Lilly is a no-brainer opportunity for investors with a long ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Here's what Wall Street analysts say about the inclusion: Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company ... Lilly said on Monday it has sued two ...

This has lagged the Medical sector's gain of 1. ... be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to be unveiled ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...